Clinical Trials Logo
  1. Home
  2. Low Grade Glioma
  3. NCT02840409

Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

Low Grade Glioma Clinical Trial

Official title:
A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG)

Clinical Trial Summary

This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy naïve pediatric patients with progressive Low Grade Glioma aged 6 months to less than18 years of age at the time of initiation of therapy. Participants will be randomized to Arm A or Arm B. Arm A includes 68 weeks of single agent Vinblastine administered once weekly IV. Arm B includes 68 weeks of Vinblastine administered weekly IV with the addition of 12 doses of Bevacizumab administered every two weeks IV for the initial 24 weeks. Randomization will take place at the time of registration taking into account NF1 and BRAF-KIAA1549-fusion status.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02840409
Study type Interventional
Source The Hospital for Sick Children
Contact
Status Active, not recruiting
Phase Phase 2
Start date August 1, 2016
Completion date August 2026
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Active, not recruiting NCT04044937 - Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms Phase 2
Terminated NCT01452854 - Ovarian Aging in Low Grade Glioma (LGG) Treated With Temozolomide
Recruiting NCT03952598 - Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy N/A
Active, not recruiting NCT03213665 - Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Recruiting NCT05964569 - Feasibility of Individualized, Model-guided Optimization of Proton Beam Treatment Planning in Patients With Low Grade Glioma Phase 2
Completed NCT02607397 - ROCOCO - Low Grade Glioma - Planning Study N/A
Active, not recruiting NCT01358058 - Proton Radiation Therapy for Gliomas N/A
Recruiting NCT03718767 - Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype Phase 2
Recruiting NCT02455245 - A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma Phase 3
Completed NCT02186262 - Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas
Terminated NCT02023905 - Everolimus With and Without Temozolomide in Adult Low Grade Glioma Phase 2
Recruiting NCT01386450 - AZD6244 in Children With Low-Grade Gliomas Phase 1/Phase 2
Completed NCT02286531 - Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma N/A
Active, not recruiting NCT04553757 - Seizure Control as a New Metric in Assessing Efficacy of Tumor Treatment in Patients With Low Grade Glioma
Not yet recruiting NCT06132685 - Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial Phase 2
Recruiting NCT04166409 - A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma Phase 3
Recruiting NCT02358187 - A Vaccine Trial for Low Grade Gliomas Phase 2
Recruiting NCT03871257 - A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma Phase 3
Terminated NCT01281982 - (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas